Description
A potent and selective histamine H1 receptor antagonist with 37,744-fold and 9,562-fold selectivity over H2 and H3, respectively (Kis = 1.3, 49,067, and 12,430 nM for H1, H2, and H3, respectively); selective for H1 receptors with less than 50% inhibition of α1-, α2-, and β1-adrenergic, dopamine D1 and D2, and serotonin 5-HT1 and 5-HT2 receptors at a concentration of 10 µM; inhibits histamine-induced phosphoinositide turnover and intracellular calcium mobilization in primary HCECs (IC50s = 1.6 and 2.9 nM, respectively); inhibits histamine-stimulated cytokine secretion by primary HCECs, including IL-6, IL-8, and GM-CSF secretion (IC50s = 2.23, 3.42, and 1.50 nM, respectively); ocular application to guinea pigs 4 hours after histamine challenge inhibits vascular permeability (ED50 = 0.019% w/v),
Formal name: 1-(2-ethoxyethyl)-2-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-1H-benzimidazole, 2E-butenedioate (1:2)
Synonyms: AL 3432A|LY188695
Molecular weight: 534.6
CAS: 87233-62-3
Purity: ≥98%
Formulation: A solid
Product Type|Biochemicals|Receptor Pharmacology|Antagonists||Research Area|Immunology & Inflammation|Allergy||Research Area|Neuroscience|Ophthalmology
